S&P 500   5,246.74
DOW   39,826.92
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,246.74
DOW   39,826.92
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,246.74
DOW   39,826.92
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,246.74
DOW   39,826.92
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
NASDAQ:ACIU

AC Immune (ACIU) Stock Price, News & Analysis

$2.91
-0.12 (-3.96%)
(As of 08:41 AM ET)
Today's Range
$2.91
$2.91
50-Day Range
$2.66
$4.15
52-Week Range
$1.78
$5.14
Volume
346 shs
Average Volume
145,009 shs
Market Capitalization
$287.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

AC Immune MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
428.1% Upside
$16.00 Price Target
Short Interest
Healthy
1.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.12mentions of AC Immune in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.75) to ($0.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

341st out of 939 stocks

Pharmaceutical Preparations Industry

151st out of 434 stocks

ACIU stock logo

About AC Immune Stock (NASDAQ:ACIU)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

ACIU Stock Price History

ACIU Stock News Headlines

AC Immune S.A.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
AC Immune SA (NASDAQ:ACIU) Short Interest Down 6.0% in February
ACIU Mar 2024 2.500 put
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
5 Little-Known Penny Stocks With Massive Upside Potential
ACIU May 2024 2.500 call
ACIU Aug 2024 2.500 call
AC Immune Ltd (ACIU)
5 Small-Cap Stocks to Play the January Effect
AC Immune (ACIU) Upgraded to Buy: Here's Why
See More Headlines
Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Next Earnings (Estimated)
4/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACIU
Employees
133
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+428.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-60,410,000.00
Pretax Margin
-366.34%

Debt

Sales & Book Value

Annual Sales
$16.48 million
Book Value
$2.12 per share

Miscellaneous

Free Float
94,350,000
Market Cap
$299.67 million
Optionable
Optionable
Beta
1.03
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Andrea Pfeifer Ph.D. (Age 67)
    Co-Founder, CEO & Director
    Comp: $1.12M
  • Mr. Christopher Roberts (Age 34)
    CFO & VP of Finance
  • Mr. Piergiorgio Donati (Age 53)
    Chief Technical Operations Officer
  • Mr. Jean-Fabien Monin (Age 53)
    Chief Administrative Officer
  • Mr. Howard Donovan (Age 48)
    Chief HR Officer
  • Ms. Madiha Derouazi (Age 51)
    Chief Scientific Officer
  • Dr. Gary Anthony Waanders Ph.D. (Age 60)
    Senior VP of Investor Relations & Corporate Communications
  • Mr. Alexandre Caratsch (Age 58)
    General Counsel
  • Mr. Julian Snow
    VP of U.S. Finance & Corporate Development
  • Dr. David T. Hickman
    Head of AD - SME

ACIU Stock Analysis - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings
or view top-rated stocks.

What is AC Immune's stock price target for 2024?

1 equities research analysts have issued twelve-month price targets for AC Immune's stock. Their ACIU share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 428.1% from the stock's current price.
View analysts price targets for ACIU
or view top-rated stocks among Wall Street analysts.

How have ACIU shares performed in 2024?

AC Immune's stock was trading at $5.00 on January 1st, 2024. Since then, ACIU stock has decreased by 39.4% and is now trading at $3.03.
View the best growth stocks for 2024 here
.

Are investors shorting AC Immune?

AC Immune saw a decrease in short interest in March. As of March 15th, there was short interest totaling 583,000 shares, a decrease of 7.2% from the February 29th total of 628,000 shares. Based on an average daily trading volume, of 152,400 shares, the days-to-cover ratio is presently 3.8 days. Approximately 1.0% of the company's shares are sold short.
View AC Immune's Short Interest
.

When is AC Immune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our ACIU earnings forecast
.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03.

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?
When did AC Immune IPO?

AC Immune (ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's stock is owned by many different retail and institutional investors. Top institutional shareholders include BVF Inc. IL (17.25%), Avidity Partners Management LP (5.29%), Platinum Investment Management Ltd. (1.79%), Goldman Sachs Group Inc. (0.02%), Goldman Sachs Group Inc. (0.02%) and Nixon Peabody Trust Co. (0.02%).

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACIU) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners